How I treat chronic myeloid leukemia in the imatinib era.
暂无分享,去创建一个
[1] J. Bajpai. Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial , 2008 .
[2] G. Rosti,et al. The effects of imatinib on pregnancy outcome. , 2008, Blood.
[3] M. Baccarani,et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells , 2007, Cancer.
[4] M. Horowitz,et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia , 2007, British journal of haematology.
[5] M. Baccarani,et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. , 2007, Blood.
[6] M. Baccarani,et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. , 2007, Blood.
[7] M. Deininger,et al. Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia. , 2007, Clinical lymphoma & myeloma.
[8] M. Baccarani,et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. , 2007, Haematologica.
[9] J. Radich,et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. , 2007, Blood.
[10] D. Bergstrom,et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. , 2007, Blood.
[11] C. Haferlach,et al. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy , 2007, Leukemia & lymphoma.
[12] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[13] P. Campbell,et al. The myeloproliferative disorders. , 2006, The New England journal of medicine.
[14] J. Seymour,et al. Increasing Frequency and Marked Stability of Complete Molecular Response Is Observed in Imatinib-Treated CML Patients with Long-Term Follow Up. , 2006 .
[15] J. Melo,et al. BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations. , 2006 .
[16] T. Brümmendorf,et al. A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib. , 2006 .
[17] L. Scapozza,et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. , 2006, Cancer research.
[18] H. Kantarjian,et al. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. , 2006, Blood.
[19] Francisco Cervantes,et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.
[20] Susan O'Brien,et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. , 2006, Blood.
[21] Tillmann Krahnke,et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. , 2006, Blood.
[22] H. Kantarjian,et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. , 2006, Blood.
[23] Brian Walters,et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.
[24] Simona Soverini,et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.
[25] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[26] K. Bhalla,et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.
[27] J. Melo,et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib , 2006, Leukemia.
[28] H. Kantarjian,et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Hongyue Dai,et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. Klein,et al. Long-term outcome after allogeneic hematopoietic cell transplantation (HCT) for CML , 2006 .
[31] J. Goldman,et al. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? , 2006, Leukemia & lymphoma.
[32] J. Mestan,et al. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. , 2005, Blood.
[33] J. Sierra,et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. , 2005, Blood.
[34] A. B. Lyons,et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. , 2005, Blood.
[35] F. Guilhot,et al. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia , 2005, Leukemia.
[36] Martin A. Nowak,et al. Dynamics of chronic myeloid leukaemia , 2005, Nature.
[37] J. Melo,et al. Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. , 2005, Blood.
[38] A. Tabilio,et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial , 2005, The Lancet.
[39] K. Gumireddy,et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] Munir Pirmohamed,et al. Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.
[41] G. Ledderose,et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease , 2004, Bone Marrow Transplantation.
[42] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[43] John P Klein,et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants , 2004, British journal of haematology.
[44] H. Kantarjian,et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. , 2004, Blood.
[45] S. Solomon,et al. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia , 2003, Bone Marrow Transplantation.
[46] Susan Branford,et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.
[47] D. Marin,et al. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. , 2003, Blood.
[48] W. Siegert,et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia , 2003, Leukemia.
[49] Susan Branford,et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.
[50] J. Radich,et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. , 2003, Blood.
[51] B. Druker,et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. , 2003, Blood.
[52] J. Ford,et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] J. Melo,et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. , 2003, Blood.
[54] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[55] Mark M. Davis,et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. , 2003, The Journal of clinical investigation.
[56] K. Krohn,et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. , 2003, Blood.
[57] N. Donato,et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.
[58] Jonas Mattsson,et al. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. , 2003, Blood.
[59] A. Nagler,et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. , 2003, Blood.
[60] H. Kantarjian,et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. , 2003, Blood.
[61] H. Kantarjian,et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. , 2002, Blood.
[62] R. Larson,et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.
[63] M. Baccarani,et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.
[64] J. Goldman,et al. Cytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia , 2002, Acta Haematologica.
[65] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[66] C. Craddock,et al. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse , 2001, British journal of haematology.
[67] C. Creaser,et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. , 2001, Blood.
[68] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[69] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[70] C. Geary. The story of chronic myeloid leukaemia , 2000, British journal of haematology.
[71] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.
[72] J. Hasford,et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.
[73] J. Melo,et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.
[74] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[75] Francisco Cervantes,et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .
[76] S. Kimura,et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. , 2007, Blood.
[77] G. Daley,et al. Chronic Myeloid Leukemia — A Brief History , 2007 .
[78] P. Loehrer. Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate , 2007 .
[79] R. Piazza,et al. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.
[80] P. Pilot,et al. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.
[81] S. Iacobelli,et al. Design and Methods , 2022 .
[82] R. Brand,et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 2006, Haematologica.
[83] J. Melo,et al. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. , 2006, Blood.
[84] B. Druker,et al. Oncogenes and Tumor Suppressors (795 articles) , 2004 .
[85] D. Marin,et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. , 2003, Haematologica.
[86] D. Marin,et al. Management decisions in chronic myeloid leukemia. , 2003, Seminars in hematology.
[87] D. Marin,et al. Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. , 2003, Haematologica.
[88] C. Anasetti. Advances in unrelated donor hematopoietic cell transplantation. , 2003, Haematologica.
[89] H. Kantarjian,et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. , 2002, Blood.
[90] D. Marin,et al. The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. , 2002, Haematologica.
[91] T. Holyoake,et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.
[92] B. Druker,et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.
[93] J. Spivak,et al. Commentary on and reprint of Nowell PC, Hungerford DA, A minute chromosome in human chronic granulocytic leukemia, in Science (1960) 132:1497 , 2000 .
[94] P. Nowell,et al. A minute chromosome in human chronic granulocytic leukemia , 1960 .
[95] K. Krohn. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses , 2022 .